STOCK TITAN
  1. Home
  2. News
  3. MGRX

Mangoceuticals Inc - MGRX STOCK NEWS

Welcome to our dedicated news page for Mangoceuticals (Ticker: MGRX), a resource for investors and traders seeking the latest updates and insights on Mangoceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mangoceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mangoceuticals's position in the market.

News
Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products
Rhea-AI Summary
Mangoceuticals, Inc. (NASDAQ: MGRX) announces a technical agreement with Emifarma S.A. de C.V for the development and testing of Mango ED products for the Mexican and Latin American markets. This marks a significant step towards obtaining certification from COFEPRIS, opening doors for expansion into multiple markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.04%
Tags
none
-
News
MangoRx Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Treatment
Rhea-AI Summary
Mangoceuticals, Inc. (NASDAQ: MGRX) introduces 'PRIME' by MangoRx, an FDA-approved oral testosterone replacement therapy treatment, targeting men with low testosterone. The company aims to tap into a significant market of men seeking alternative TRT options, leveraging its telehealth platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.03%
Tags
fda approval
-
News
MangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue Growth
Rhea-AI Summary
Mangoceuticals, Inc. (NASDAQ: MGRX) launches a direct-to-clinics sales division, allowing doctors to prescribe MangoRx products from their offices. The company aims to increase recurring revenues and reduce customer acquisition costs by deploying a sales force to penetrate men’s health and wellness clinics across the US. The newly developed clinic prescribing system enables practitioners to prescribe MangoRx products, including the recently launched 'PRIME', by MangoRx, powered by Kyzatrex®️.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
acquisition
News
MANGORX AWARDS SAN FRANCISCO TEAM FREE MANGORX ED PRODUCTS FOR ONE YEAR FOLLOWING BIG GAME LOSS TO KANSAS CITY
Rhea-AI Summary
Mangoceuticals, Inc. (Nasdaq: MGRX) offers San Francisco players and coaches a free one-year supply of its 'Mango' erectile dysfunction product following a Big Game loss. Fans can also get 3 free Mango pills with a special discount code 'SB58'. The product contains active ingredients from Cialis and Viagra, compounded with Oxytocin and L-Arginine in a Mango-flavored rapid dissolve tablet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.36%
Tags
none
-
News
MANGORX TO OFFER THE BIG GAME’S LOSING TEAM A FREE ONE YEAR SUPPLY OF ITS ED PRODUCT, MANGO, TO HELP RAISE… SPIRITS
Rhea-AI Summary
Mangoceuticals, Inc. (Nasdaq: MGRX) announces a promotion offering the losing team of the Big Game a free one-year supply of its Mango ED products. Fans can also get a special discount code equal to the game's point difference. The company's uniquely formulated Mango ED products are designed to help men tackle performance issues in the bedroom. MangoRx will also be the marquee sponsor for several Barstool Sports' week-long programming surrounding the Big Game in Las Vegas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.59%
Tags
none
-
News
MangoRx Accepting Pre Orders for its “PRIME”, by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Product
Rhea-AI Summary
Mangoceuticals, Inc. (NASDAQ: MGRX) is offering 2 months of free ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ for the first 1,000 male subscribers interested in subscribing to the oral testosterone replacement protocol. The company is also providing discounted prices for a minimally invasive FDA approved at-home blood collection test kit through their nationwide lab partnership with Trybe Labs. Jacob Cohen, MangoRx’s Co-Founder and CEO, expressed excitement about the official PRIME launch and the one-time promotion for the first 1,000 interested subscribers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.03%
Tags
fda approval
News
MangoRx’s Brand and Products to be Featured by Barstool Sports in Week of Programming Around the Biggest Sports Event of the Year on February 11
Rhea-AI Summary
Mangoceuticals, Inc. (Nasdaq: MGRX) announces its sponsorship of Barstool Sports' week-long programming schedule surrounding the Big Game in Las Vegas, featuring its FDA-approved oral Testosterone Replacement 'Prime' by MangoRx, powered by Kyzatrex. The company will be a Marquee Sponsor and will be featured across Barstool programming during the week of the Super Bowl, reaching an estimated number of over 7 million views and impressions. The partnership aims to showcase 'Prime' to the passionate fans of Barstool Sports and expand broad-based consumer access to this revolutionary therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.83%
Tags
none
-
News
Mangoceuticals, Inc. Announces Pricing of $1,200,000 Public Offering
Rhea-AI Summary
Mangoceuticals, Inc. (Nasdaq: MGRX) announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $0.30 per share, with aggregate gross proceeds of $1,200,000 to the Company. The Company has also granted the underwriters a 45-day option to purchase up to an additional 600,000 shares of its common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.96%
Tags
offering
-
News
MANGOCEUTICALS TO INTRODUCE “PRIME”, POWERED BY KYZATREX®️ (CIII TESTOSTERONE UNDECANOATE CAPSULES), FOR AN FDA APPROVED ORAL TESTOSTERONE REPLACEMENT THERAPY (TRT) PRODUCT
Rhea-AI Summary
Mangoceuticals, Inc. (NASDAQ: MGRX) announces a marketing agreement with Marius Pharmaceuticals to launch KYZATREX, an FDA-approved oral Testosterone Replacement Therapy, under the program PRIME by MangoRx. KYZATREX is expected to be available on MangoRx's telemedicine platform starting January 31, 2024. The new therapy aims to address testosterone deficiency in men, with a focus on providing a convenient and effective treatment option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
fda approval
News
Mangoceuticals Launches MangoRx Mexico Subsidiary, Paving the Way for Over-the-Counter Retail of Erectile Dysfunction Line of Products in Latin America
Rhea-AI Summary
Mangoceuticals, Inc. (NASDAQ: MGRX) is expanding its sales access across Latin America with the establishment of its subsidiary, MangoRx Mexico, aiming to tap into the Mexican market for men's health and wellness products, particularly its uniquely formulated hair growth product 'GROW' and erectile dysfunction (ED) drug 'Mango'. The company has engaged Diaz Reus International Law Firm for establishing its subsidiary presence in Mexico and is in the process of establishing manufacturing and distribution partnerships. The estimated annual market size in Mexico for ED pharmaceutical products is USD $216 million with approximately 24 million units sold annually and growing at a rate of 4% per year at an average sales price of USD $8.50 per unit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
none
Stock MGRX logo
Mangoceuticals Inc

Nasdaq:MGRX

MGRX Rankings

N/A Ranked by Market Cap
#5293 Ranked by Stock Gains
N/A Ranked by Dividends

MGRX Stock Data

5.97M
13.19M
41.39%
0.48%
3.01%
Pharmacies and Drug Stores
Retail Trade
Link
United States
Dallas